217 related articles for article (PubMed ID: 14985394)
1. The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation.
Sermijn E; Goelen G; Teugels E; Kaufman L; Bonduelle M; Neyns B; Poppe B; De Paepe A; De Grève J
J Med Genet; 2004 Mar; 41(3):e23. PubMed ID: 14985394
[No Abstract] [Full Text] [Related]
2. Pretest genetic counseling informs patients with BRCA mutation.
Printz C
Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
[No Abstract] [Full Text] [Related]
3. Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients.
Landsbergen K; Verhaak C; Kraaimaat F; Hoogerbrugge N
Fam Cancer; 2005; 4(2):115-9. PubMed ID: 15951961
[TBL] [Abstract][Full Text] [Related]
4. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
[TBL] [Abstract][Full Text] [Related]
5. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
[TBL] [Abstract][Full Text] [Related]
6. Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain.
Sanz J; Ramón y Cajal T; Torres A; Darder E; Gadea N; Velasco A; Fortuny D; López C; Fisas D; Brunet J; Alonso MC; Balmaña J
Fam Cancer; 2010 Sep; 9(3):297-304. PubMed ID: 20091130
[TBL] [Abstract][Full Text] [Related]
7. Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems.
Hallowell N; Ardern-Jones A; Eeles R; Foster C; Lucassen A; Moynihan C; Watson M
Clin Genet; 2005 Jun; 67(6):492-502. PubMed ID: 15857416
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
Leegte B; van der Hout AH; Deffenbaugh AM; Bakker MK; Mulder IM; ten Berge A; Leenders EP; Wesseling J; de Hullu J; Hoogerbrugge N; Ligtenberg MJ; Ardern-Jones A; Bancroft E; Salmon A; Barwell J; Eeles R; Oosterwijk JC
J Med Genet; 2005 Mar; 42(3):e20. PubMed ID: 15744030
[No Abstract] [Full Text] [Related]
9. Cancer genetics knowledge and beliefs and receipt of results in Ashkenazi Jewish individuals receiving counseling for BRCA1/2 mutations.
Kelly K; Leventhal H; Marvin M; Toppmeyer D; Baran J; Schwalb M
Cancer Control; 2004; 11(4):236-44. PubMed ID: 15284715
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
11. Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis.
Quinn GP; Vadaparampil ST; Bower B; Friedman S; Keefe DL
Minerva Med; 2009 Oct; 100(5):371-83. PubMed ID: 19910890
[TBL] [Abstract][Full Text] [Related]
12. Predictors of participation in psychosocial telephone counseling following genetic testing for BRCA1 and BRCA2 mutations.
Halbert CH; Wenzel L; Lerman C; Peshkin BN; Narod S; Marcus A; Corio C; Demarco T; Bellamy S
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):875-81. PubMed ID: 15159322
[TBL] [Abstract][Full Text] [Related]
13. Attitudes toward the genetic testing of children among adults in a Utah-based kindred tested for a BRCA1 mutation.
Hamann HA; Croyle RT; Venne VL; Baty BJ; Smith KR; Botkin JR
Am J Med Genet; 2000 May; 92(1):25-32. PubMed ID: 10797419
[TBL] [Abstract][Full Text] [Related]
14. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
Olopade OI
Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
[No Abstract] [Full Text] [Related]
15. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
[TBL] [Abstract][Full Text] [Related]
16. Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer.
Claes E; Evers-Kiebooms G; Decruyenaere M; Denayer L; Boogaerts A; Philippe K; Legius E
Behav Med; 2005; 31(3):93-105. PubMed ID: 16252621
[TBL] [Abstract][Full Text] [Related]
17. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
Høberg-Vetti H; Bjorvatn C; Fiane BE; Aas T; Woie K; Espelid H; Rusken T; Eikesdal HP; Listøl W; Haavind MT; Knappskog PM; Haukanes BI; Steen VM; Hoogerbrugge N
Eur J Hum Genet; 2016 Jun; 24(6):881-8. PubMed ID: 26350514
[TBL] [Abstract][Full Text] [Related]
18. Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
Nippert I; Schlegelberger B;
Community Genet; 2003; 6(4):249-58. PubMed ID: 15331871
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
[TBL] [Abstract][Full Text] [Related]
20. Psychosocial issues associated with genetic testing for breast and ovarian cancer risk: an integrative review.
Pasacreta JV
Cancer Invest; 2003; 21(4):588-623. PubMed ID: 14533449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
